Lexeo Therapeutics, a clinical stage genetic medicine company, has announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors.
Van Hauwermeiren has over two decades of experience in both general management and business development across the life sciences and consumer goods industries. He has overseen the development and launch of argenx's first commercial product, efgartigimod, for the treatment of multiple severe autoimmune diseases, and has expanded the company’s footprint across Europe, the U.S., and Asia.
During his time at argenx, Van Hauwermeiren has secured more than $4 billion in funding through equity raises and business development transactions with major pharmaceutical companies. Prior to argenx, he held roles with increasing levels of responsibility at Ablynx and Procter & Gamble.
Van Hauwermeiren's appointment comes as Lexeo Therapeutics looks to progress its pipeline into later stages of clinical and commercial development. The company is dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
This strategic appointment brings a wealth of experience to Lexeo's Board of Directors, which will be invaluable as the company enters its next phase of growth. As a result of these announcements, the company's shares have moved 4.0% on the market, and are now trading at a price of $15.49. For the full picture, make sure to review Lexeo Therapeutics's 8-K report.
